While hypoglycemia isn't a typical effect of Ozempic alone, combinations can change risk
What this research adds is a more complete picture of how patients experience them in the real world, which is valuable both for clinicians monitoring patients and for patients advocating for themselves
One of the limitations of the current drugs is that individual variation, possibly including how people express target receptors or respond to their corresponding hormones, can lead to lesser than desired weight loss outcomes in many patients, said Martin Beinborn, visiting scholar in the Department of Chemistry
Yes, you can qualify for semaglutide at BMI 28 if you have at least one weight-related health condition
Results Participant characteristics The first cohort, comparing patients using GLP-1RA to those using DPP-4i, initially included 5,394,231 patients diagnosed with diabetes from the TriNetX database
Likely not a fit: Patients with significant obesity or a metabolic condition will need the full-dose efficacy of standard GLP-1 regimens